List of Excipients in Branded Drug HALOBETASOL PROPIONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma	HALOBETASOL PROPIONATE	halobetasol propionate	51862-606	ALCOHOL
Mayne Pharma	HALOBETASOL PROPIONATE	halobetasol propionate	51862-606	BENZOIC ACID
Mayne Pharma	HALOBETASOL PROPIONATE	halobetasol propionate	51862-606	CETOSTEARYL ALCOHOL

Generic Drugs Containing HALOBETASOL PROPIONATE

Company	Ingredient	NDC	Excipient
Fougera Pharmaceuticals Inc	halobetasol propionate	0168-0355	CETYL ALCOHOL
Fougera Pharmaceuticals Inc	halobetasol propionate	0168-0355	DIAZOLIDINYL UREA
Fougera Pharmaceuticals Inc	halobetasol propionate	0168-0355	GLYCERIN

What are the Most Frequently-Used Excipients in HALOBETASOL PROPIONATE?

# Of NDCs	Excipient
1	ALCOHOL
4	ALLYL PENTAERYTHRITOL
16	ALUMINUM STEARATE

Halobetasol Propionate Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Halobetasol propionate is a super-high-potency topical corticosteroid with established demand in plaque psoriasis and corticosteroid-responsive dermatoses. Commercial opportunity is concentrated in differentiated vehicles, lower-strength formulations, combination products, spray or foam delivery, preservative strategies, and generic products that improve tolerability or application convenience. The active ingredient itself is mature; formulation performance and regulatory execution determine most of the remaining value.

What is the commercial status of halobetasol propionate?

Halobetasol propionate is approved in multiple topical dosage forms, including ointment, cream, lotion, foam, and combination lotion products. Current U.S. products include:

Product	Active ingredient	Strength	Dosage form	Commercial relevance
Ultravate and generic equivalents	Halobetasol propionate	0.05%	Ointment, cream, lotion	Established high-potency steroid market
Lexette	Halobetasol propionate	0.05%	Aerosol foam	Fast-spreading, cosmetically differentiated vehicle
Bryhali	Halobetasol propionate	0.01%	Lotion	Lower-strength, lotion-based lifecycle product
Duobrii	Halobetasol propionate and tazarotene	0.01% / 0.045%	Lotion	Combination product for plaque psoriasis

The 0.05% products are classified as super-high-potency topical corticosteroids. The 0.01% lotion products use lower halobetasol concentration but remain potent prescription treatments. FDA labeling limits treatment duration and weekly quantity because prolonged or extensive use can cause local adverse effects and systemic corticosteroid exposure.[1-4]

Which excipients are used in halobetasol propionate products?

The excipient system depends on the delivery vehicle. Halobetasol propionate is a highly potent, lipophilic corticosteroid with limited aqueous solubility. Formulators therefore commonly use oil-rich vehicles, solubilizers, emulsifiers, humectants, rheology modifiers, and packaging systems that support uniform dosing.

Vehicle	Typical excipient classes	Technical purpose	Commercial advantage
Ointment	Petrolatum, mineral oil, paraffin, waxes	Occlusion, emollience, drug solubilization	Strong penetration and low preservative burden
Cream	Oil phase, water phase, fatty alcohols, emulsifiers, glycols	Emulsion formation and skin feel	More acceptable than ointment for many patients
Lotion	Water, emollients, emulsifiers, humectants, viscosity modifiers	Spreadability and rapid application	Better body-area coverage and cosmetic profile
Foam	Volatile propellants, surfactants, fatty alcohols, glycols	Rapid evaporation and low-residue delivery	Useful for scalp and hair-bearing areas
Combination lotion	Emulsion system, antioxidants, chelators, pH adjusters	Stabilization of two active ingredients	Product differentiation and broader psoriasis positioning

The exact excipient composition is product-specific and should be evaluated against the FDA-approved labeling and inactive-ingredient records. Lexette, for example, uses a foam architecture with fatty alcohols, propylene glycol, surfactant components, water, preservatives or preservative-supporting agents, and hydrocarbon propellant technology.[2] Bryhali uses a lotion base designed to spread over larger areas while supporting the 0.01% active concentration.[3] Duobrii must stabilize both halobetasol propionate and tazarotene, which increases formulation and packaging complexity.[4]

What excipient strategy best fits halobetasol propionate?

The most defensible strategy is to select excipients around the intended treatment site, dosing frequency, and patient preference rather than relying only on conventional steroid vehicles.

Ointment strategy

Ointments remain technically attractive because halobetasol propionate is lipophilic and the anhydrous base reduces hydrolytic risk. Petrolatum and mineral oil systems can provide:

• High drug-solubilizing capacity
• Occlusion that increases skin hydration
• Low microbial risk compared with water-containing emulsions
• Simple manufacturing
• Lower preservative requirements

The principal commercial weakness is poor cosmetic acceptability. Greasiness, residue on clothing, and difficulty applying the product to hair-bearing areas can reduce adherence. An improved ointment opportunity would focus on lower tack, lower transfer, easier wash-off, or a more elegant semi-occlusive texture without materially reducing delivery.

Cream strategy

Creams offer a compromise between penetration and consumer acceptability. Relevant excipient levers include:

• Fatty alcohol selection for structure and skin feel
• Glycol selection for active solubilization
• Emulsifier choice for physical stability
• Humectants for hydration
• Silicone or ester components for reduced tack
• Preservative selection based on irritation and sensitization risk

Cream products can compete effectively where physicians want high potency but patients reject ointments. A cream formulation with a low-residue finish may have commercial value in intertriginous or visible areas, subject to labeling and potency constraints.

Lotion strategy

Lotion is the strongest platform for expanding treatment-area coverage. It is suitable for trunk, limbs, and other areas where a thin, spreadable product is preferred. The primary excipient challenges are:

• Maintaining uniform suspension or solution of halobetasol propionate
• Preventing creaming, sedimentation, or phase separation
• Controlling viscosity without slowing application
• Preserving the formulation
• Limiting sting on compromised skin
• Maintaining dose uniformity through the container life

Bryhali demonstrates the commercial potential of a lower-strength 0.01% lotion. The product supports differentiation through vehicle, concentration, and intended use rather than through a new active ingredient.[3]

Foam strategy

Foam provides a distinct opportunity for scalp psoriasis and hair-bearing areas. The vehicle collapses rapidly, reduces residue, and can be distributed without the rubbing required for ointments or creams.

Key excipient and device considerations include:

• Propellant selection and pressure profile
• Foam density and collapse time
• Valve performance
• Container compatibility
• Cold-temperature behavior
• Dose reproducibility
• Flammability labeling
• Skin cooling or irritation from volatile components

Foam products can command a commercial premium when they improve application convenience. The major development risk is that the container, valve, actuator, and formulation function as one delivery system. A formulation change can alter spray pattern, foam stability, delivered dose, or residual content.

What formulation patents protect halobetasol propionate products?

Halobetasol propionate’s original compound protection is no longer the main barrier to entry. Commercial protection has shifted to:

1. Composition-of-matter and formulation patents for specific vehicles.
2. Combination-product patents covering halobetasol propionate with tazarotene.
3. Foam and aerosol delivery systems.
4. Use patents covering treatment regimens or body sites.
5. Container, valve, and metered-delivery configurations.
6. Manufacturing processes that improve active uniformity or physical stability.

The Orange Book is the principal source for patents and regulatory exclusivity associated with approved drug products.[5] Product-specific patent review should distinguish between listed patents, expired patents, patents subject to pediatric exclusivity, and patents that may be vulnerable to invalidity or non-infringement arguments.

A generic applicant can face different barriers depending on dosage form:

Product type	Likely regulatory pathway	Main technical barrier
Ointment	ANDA	Q1/Q2 sameness, assay uniformity, performance equivalence
Cream	ANDA	Emulsion microstructure, rheology, release and permeation
Lotion	ANDA	Physical stability, globule size, viscosity, drug distribution
Foam	ANDA or product-specific pathway	Device performance, foam characteristics, actuation dose
Combination lotion	ANDA or 505(b)(2), depending on product and reference strategy	Dual-active stability, comparative clinical or performance evidence

Paragraph IV risk is highest when a generic sponsor targets a commercially important foam or combination product before all listed patents expire. An ANDA sponsor must evaluate each Orange Book patent separately and develop a non-infringement, invalidity, or unenforceability position where applicable. Litigation exposure is generally more material for differentiated lifecycle products than for legacy ointments and creams.

When does halobetasol propionate lose exclusivity?

The active ingredient has long been off-patent. The relevant exclusivity question concerns individual products and formulations.

Exclusivity layer	Status and commercial implication
Active ingredient	Mature and available for generic development
Legacy ointment and cream	Generally exposed to generic competition
Lotion products	Protected primarily by formulation, use, and product-specific patents
Foam products	Exposed to device, formulation, and patent barriers
Halobetasol/tazarotene combination	Higher barrier because of two-active-ingredient formulation and product-specific protection
Regulatory exclusivity	Must be checked by product in FDA records and the Orange Book

Patent expiration dates should be taken from current Orange Book entries and the underlying patent records, not inferred from the original approval date. A product can remain commercially protected after the active ingredient is generic if a formulation or combination patent remains enforceable.

What excipient opportunities exist for generic manufacturers?

Generic manufacturers have five practical routes to compete.

1. Match the reference vehicle

The lowest-risk route is a composition closely matching the reference product. This can simplify comparative performance work and reduce physician or pharmacy switching concerns. The disadvantage is limited differentiation and greater price competition.

2. Improve cosmetic properties

A generic cream, lotion, or ointment can differentiate through:

• Lower tack
• Faster rub-in
• Reduced whitening
• Lower transfer to clothing
• Improved wash-off
• Reduced odor
• Better scalp application

These changes must not compromise active uniformity, release, stability, or therapeutic performance.

3. Develop a preservative strategy

Water-containing halobetasol products require microbial control. Potential approaches include conventional preservatives, preservative combinations, reduced-water systems, airless packaging, or preservative-free formats where technically feasible.

Preservative-free positioning may have value for patients with sensitive or damaged skin, but it increases packaging and microbiological-control requirements. Airless pumps can reduce repeated environmental exposure, yet they introduce extractables, leachables, priming, residual-content, and dose-uniformity work.

4. Optimize the delivery device

For foam and lotion products, the package is part of the product. Opportunities include:

• Metered pumps
• Non-aerosol foams
• Precision actuators
• One-handed application
• Larger treatment-area dispensers
• Packaging designed for scalp use

A device-centered strategy can create defensible intellectual property even when the active ingredient and basic vehicle are generic.

5. Use a 505(b)(2) lifecycle strategy

A 505(b)(2) application may be appropriate for a reformulated product, new strength, new combination, or delivery system where the sponsor cannot rely entirely on an ANDA pathway. The approach can support a new clinical positioning but requires a stronger evidence package and may face listed-patent and exclusivity issues.[6]

How does halobetasol propionate compare with competing topical corticosteroids?

Halobetasol competes with clobetasol propionate, betamethasone dipropionate, fluocinonide, mometasone furoate, and other topical corticosteroids. Its commercial position is strongest where high potency is needed for limited-duration treatment.

Attribute	Halobetasol propionate	Clobetasol propionate	Mometasone furoate
Potency class	Super-high potency	Super-high potency	High to medium-high, depending on vehicle
Common strength	0.05% or 0.01%	0.05%	0.1%
Differentiated forms	Foam, lotion, combination lotion	Cream, ointment, solution, foam and other forms	Cream, ointment, lotion, solution
Main opportunity	Vehicle and combination innovation	Broad generic availability and vehicle competition	Tolerability and broader-use positioning
Main risk	Duration and quantity restrictions	Intense price competition	Substitution based on clinical familiarity

Halobetasol products can command stronger commercial positioning when they combine high potency with a patient-preferred vehicle. Without a meaningful vehicle advantage, the product is vulnerable to substitution by established generic corticosteroids.

What manufacturing and formulation barriers affect commercial entry?

The main manufacturing risks are not related to synthesis of halobetasol propionate. They arise during semisolid processing and filling.

Critical process variables include:

• Order and temperature of phase addition
• Homogenization energy
• Cooling rate
• Active incorporation
• Particle-size control
• Deaeration
• Bulk-hold time
• Fill-weight control
• Container closure integrity

For emulsions, active distribution can vary if halobetasol propionate partitions unevenly between phases. For suspensions, particle-size distribution and sedimentation affect dose uniformity and release. For foams, pressure, valve geometry, propellant ratio, and product viscosity determine delivered dose and foam quality.

Analytical programs should include assay, impurities, viscosity, pH where applicable, particle size, globule size, rheology, microbial limits, preservative effectiveness, in vitro release testing, and in vitro permeation testing. FDA guidance supports the use of comparative product-performance data in topical generic development, but the appropriate evidence package depends on dosage form and reference product.[7]

What commercial opportunities are strongest?

The highest-value opportunities are differentiated products that solve a recognized application problem.

Opportunity	Market rationale	Development priority
Low-residue lotion	Supports larger treatment areas and better adherence	High
Non-aerosol foam	Avoids some propellant and flammability concerns	Medium-high
Scalp-focused delivery system	Addresses hair-bearing-area application	High
Preservative-reduced formulation	Targets sensitive-skin users	Medium
Combination product	Adds nonsteroidal mechanism through tazarotene or another active	High but higher risk
Lower-transfer ointment	Retains occlusion with improved acceptability	Medium
Generic reference-matched products	Fastest route to volume	High but price-sensitive
Metered-dose package	Improves dose control and supports device IP	Medium-high

Combination products have the greatest potential for brand differentiation but also carry the highest formulation, clinical, patent, and regulatory burden. Standalone lotion and foam products offer a more accessible path for generic or specialty-pharma development.

What FDA regulatory status applies to halobetasol propionate?

Halobetasol propionate is an FDA-approved prescription topical corticosteroid. It is not an over-the-counter product. Product-specific approval status, labeling, therapeutic equivalence, patents, and exclusivity are recorded in FDA databases and approved labeling.[1-5]

The principal regulatory issues are:

• Super-high-potency corticosteroid warnings
• Maximum duration of use
• Maximum weekly quantity
• Pediatric restrictions
• Application-site limitations
• HPA-axis suppression risk
• Local adverse reactions
• Comparative performance for generic topical products
• Combination-product evidence requirements

There is no biosimilar pathway for halobetasol propionate because it is a chemically synthesized small molecule. Competitive entry occurs through ANDA products, 505(b)(2) products, or other applicable small-molecule pathways.

Key Takeaways

• Halobetasol propionate is a mature active ingredient with continuing value in differentiated topical delivery.
• Ointments provide technical simplicity and strong occlusion but have weaker cosmetic acceptance.
• Lotions and foams offer the clearest commercial differentiation.
• The 0.01% lotion platform supports lifecycle management by combining lower active concentration with a more acceptable vehicle.
• Foam products create opportunities in scalp and hair-bearing areas but add device and packaging complexity.
• Combination products such as halobetasol propionate/tazarotene have higher commercial potential and higher regulatory and patent risk.
• Generic entry risk is high for legacy ointments and creams and more dependent on patents, device performance, and formulation equivalence for lotions and foams.
• The strongest excipient strategies improve spreadability, residue, transfer, stability, dose uniformity, or patient adherence without weakening topical delivery.

FAQs

Can halobetasol propionate be formulated as a preservative-free cream?

Yes, but a preservative-free cream requires an alternative microbial-control strategy, such as reduced water activity, sterile or controlled manufacturing, or protective packaging. The approach must preserve stability, dose uniformity, and microbiological quality throughout the labeled shelf life.

Is halobetasol propionate suitable for a transdermal patch?

Its high potency means that a patch could deliver pharmacologically active quantities with a relatively small amount of drug. The principal barriers are dose control, irritation, occlusion-related exposure, and the risk of excessive systemic absorption. A patch would likely require a new product development pathway rather than a conventional generic approach.

Which excipients can improve halobetasol propionate skin penetration?

Glycols, selected lipids, fatty esters, surfactants, and occlusive hydrocarbons can alter partitioning and skin hydration. The optimal system depends on whether the product is intended to increase epidermal delivery, reduce residue, or control exposure. Penetration enhancement must be balanced against irritation and systemic absorption.

What is the best dosage form for scalp psoriasis?

Foam is generally the strongest commercial format for scalp and hair-bearing areas because it spreads rapidly and leaves less residue. Solutions, sprays, and lotions can compete where lower packaging complexity or lower manufacturing cost is more important.

Can a generic company change the excipients in an approved halobetasol product?

A generic applicant generally must satisfy the applicable sameness and performance requirements for the reference product. Excipients may differ within regulatory limits, but a material formulation difference can increase the need for comparative studies or move development toward a 505(b)(2) strategy.

References

1. U.S. Food and Drug Administration. (2023). Ultravate (halobetasol propionate) ointment, cream, and lotion prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Lexette (halobetasol propionate) aerosol foam prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Bryhali (halobetasol propionate) lotion prescribing information. FDA.

4. U.S. Food and Drug Administration. (2023). Duobrii (halobetasol propionate and tazarotene) lotion prescribing information. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.

7. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development: Halobetasol propionate topical products. FDA.